Literature DB >> 31299018

Oxycodone, fentanyl, and morphine amplify established neuropathic pain in male rats.

Suzanne M Green-Fulgham1, Jayson B Ball1, Andrew J Kwilasz1, Timothy Fabisiak2, Steven F Maier1, Linda R Watkins1, Peter M Grace2.   

Abstract

Opioids are widely prescribed for chronic pain, including neuropathic pain, despite growing evidence of long-term harm. Previous preclinical studies have documented exacerbation of nociceptive hypersensitivity, including that induced by peripheral nerve injury, by morphine. The present series of behavioral studies sought to replicate and extend our prior research, which demonstrated a multimonth exacerbation of nociceptive hypersensitivity by a 5-day course of morphine initiated 10 days after nerve injury. The current studies demonstrate that enduring exacerbation of nociceptive hypersensitivity is not restricted to morphine, but rather is also created by the clinically relevant opioids fentanyl and oxycodone when these are likewise administered for 5 days beginning 10 days after nerve injury. Furthermore, enduring exacerbation of nociceptive hypersensitivity is also observed when the same dosing regimen for either morphine, fentanyl, or oxycodone begins 1 month after nerve injury. Finally, a striking result from these studies is that no such exacerbation of nociceptive hypersensitivity occurs when either morphine, fentanyl, or oxycodone dosing begins at the time of nerve injury. These results extend our previous findings that morphine exacerbates nociceptive hypersensitivity to the clinically relevant opioids fentanyl and oxycodone when administered after the development of nociceptive hypersensitivity, while also providing possible clinically relevant insight into when these opioids can be safely administered and not exacerbate neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31299018      PMCID: PMC7053537          DOI: 10.1097/j.pain.0000000000001652

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   7.926


  52 in total

1.  Fitting the psychometric function.

Authors:  B Treutwein; H Strasburger
Journal:  Percept Psychophys       Date:  1999-01

2.  Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats.

Authors:  A A Megens; K Artois; J Vermeire; T Meert; F H Awouters
Journal:  J Pain Symptom Manage       Date:  1998-04       Impact factor: 3.612

3.  A novel animal model of graded neuropathic pain: utility to investigate mechanisms of population heterogeneity.

Authors:  Peter M Grace; Mark R Hutchinson; Jim Manavis; Andrew A Somogyi; Paul E Rolan
Journal:  J Neurosci Methods       Date:  2010-09-09       Impact factor: 2.390

4.  Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes.

Authors:  Lillian Huang; Stephen R Edwards; Maree T Smith
Journal:  Pharm Res       Date:  2005-07-29       Impact factor: 4.200

Review 5.  Pain regulation by non-neuronal cells and inflammation.

Authors:  Ru-Rong Ji; Alexander Chamessian; Yu-Qiu Zhang
Journal:  Science       Date:  2016-11-04       Impact factor: 47.728

6.  Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat.

Authors:  A J Reeve; S Patel; A Fox; K Walker; L Urban
Journal:  Eur J Pain       Date:  2000       Impact factor: 3.931

7.  Protraction of neuropathic pain by morphine is mediated by spinal damage associated molecular patterns (DAMPs) in male rats.

Authors:  Peter M Grace; Keith A Strand; Erika L Galer; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2017-08-30       Impact factor: 7.217

Review 8.  Toll-like receptors and their role in persistent pain.

Authors:  Michael J Lacagnina; Linda R Watkins; Peter M Grace
Journal:  Pharmacol Ther       Date:  2017-10-04       Impact factor: 12.310

9.  Morphine amplifies mechanical allodynia via TLR4 in a rat model of spinal cord injury.

Authors:  Amanda Ellis; Peter M Grace; Julie Wieseler; Jacob Favret; Kendra Springer; Bryce Skarda; Monica Ayala; Mark R Hutchinson; Scott Falci; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2016-08-09       Impact factor: 7.217

Review 10.  Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.

Authors:  Nanna B Finnerup; Nadine Attal; Simon Haroutounian; Ewan McNicol; Ralf Baron; Robert H Dworkin; Ian Gilron; Maija Haanpää; Per Hansson; Troels S Jensen; Peter R Kamerman; Karen Lund; Andrew Moore; Srinivasa N Raja; Andrew S C Rice; Michael Rowbotham; Emily Sena; Philip Siddall; Blair H Smith; Mark Wallace
Journal:  Lancet Neurol       Date:  2015-01-07       Impact factor: 44.182

View more
  6 in total

Review 1.  Does Traumatic Brain Injury Cause Risky Substance Use or Substance Use Disorder?

Authors:  Christopher M Olsen; John D Corrigan
Journal:  Biol Psychiatry       Date:  2021-07-21       Impact factor: 13.382

2.  Pain Trends Among American Adults, 2002-2018: Patterns, Disparities, and Correlates.

Authors:  Anna Zajacova; Hanna Grol-Prokopczyk; Zachary Zimmer
Journal:  Demography       Date:  2021-04-01

Review 3.  Physical work conditions and disparities in later life functioning: Potential pathways.

Authors:  Theresa Andrasfay; Nina Raymo; Noreen Goldman; Anne R Pebley
Journal:  SSM Popul Health       Date:  2021-12-04

4.  Suppression of active phase voluntary wheel running in male rats by unilateral chronic constriction injury: Enduring therapeutic effects of a brief treatment of morphine combined with TLR4 or P2X7 antagonists.

Authors:  Suzanne M Green-Fulgham; Jayson B Ball; Steven F Maier; Kenner C Rice; Linda R Watkins; Peter M Grace
Journal:  J Neurosci Res       Date:  2020-06-13       Impact factor: 4.164

5.  Sociology of Chronic Pain.

Authors:  Anna Zajacova; Hanna Grol-Prokopczyk; Zachary Zimmer
Journal:  J Health Soc Behav       Date:  2021-07-20

Review 6.  Targeting Chemokines and Chemokine GPCRs to Enhance Strong Opioid Efficacy in Neuropathic Pain.

Authors:  Martina Vincenzi; Michele Stanislaw Milella; Ginevra D'Ottavio; Daniele Caprioli; Ingrid Reverte; Daniela Maftei
Journal:  Life (Basel)       Date:  2022-03-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.